Atmo Biosciences’ ingestible gas-sensing capsule to be used in Swedish IBS trial led by Professor Magnus Simrén
Atmo Biosciences’ world-first ingestible gas-sensing capsule is being used in a clinical trial led by renowned gastroenterologist Professor Magnus Simrén currently underway at Sweden’s University of Gothenburg.
The trial named “The effects of carbohydrates in irritable bowel syndrome” is using the Atmo Gas Capsule digital biomarker platform to profile gases within the gut to help understand the mechanisms and benefits of carbohydrates in people with Irritable Bowel Syndrome (IBS), and the link to gut microbiota and function.
IBS affects hundreds of millions of people globally, and most people with IBS report that specific food items can trigger their symptoms. For the last decade, primary care physicians and gastroenterologists have increasingly recommended dietary treatments to their IBS patients.
Carbohydrates are the sugars, starches and fibres found in fruits, grains, vegetables and milk products. Carbohydrates are essential since they are the main source of energy for the body. However, some carbohydrates are thought to trigger symptoms in people with IBS. On the other hand, some carbohydrates are thought to be beneficial, especially for the gut-microbiota diversity.
In this study, trial participants will spend two weeks on a low carbohydrates diet, before receiving one out of two types of carbohydrates, in addition to the low carbohydrates diet for a further 10 days. The Atmo Gas Capsule will be administered before the low carbohydrates diet and after the reintroduction of the two types of carbohydrates. The capsule will continuously profile gases as it passes through the gastrointestinal tract, transmitting the data to the cloud in real-time for aggregation and analysis.
Professor Simrén, who is also on the Board of the Rome Foundation, said it would be the first time an ingestible capsule that can sense intestinal gas will be used in a clinical trial in Europe.
“Analysing intestinal gases in the colon with Atmo’s gas-sensing capsule will lead to better understanding of microbiota alterations induced by carbohydrates and its effects on colonic function, and help reveal the beneficial mechanisms of carbohydrates in IBS,” Professor Simrén said.
“Under current treatment methods, IBS patients are often prescribed restrictive diets that limit intake of lots of common fruits, vegetables, and dairy products. A positive result in this trial could lead to a more personalized low-carbohydrates diet by preserving beneficial carbohydrates or to new therapeutic treatments for the benefit of IBS patients.”
Atmo Biosciences CEO Mal Hebblewhite said he was excited to have Atmo’s technology included in the University of Gothenburg trial.
“This is a win for Atmo, the University of Gothenburg and the millions of IBS sufferers around the world. Our technology unlocks new datasets that could lead to a better understanding of carbohydrates sensitivity and their impact on the microbiome in IBS. We’re delighted to be working with Professor Simrén and his team at the University of Gothenburg.”
Are you a person with IBS and do you live in the Gothenburg region, Sweden? Please send an email (marked with ‘Atmo study’) to magtarmlab.su@vgregion.se if you are interested in participating.
-
Most popular related searches
Related products
Related news
-
Creative Proteomics: GutFlora Omics Platform Launches Virome Sequencing Service to Investigate Gut Microbiota
GutFlora Omics Platform belongs to Creative Proteomics. With more than 10 years of experience in providing advanced multi-omics services, the GutFlora Omics Platform offers services and support to customers through comprehensive intestinal flora research solutions. GutFlora Omics Platform recently announced the launch of virome sequencing service to better study gut microbiota. The gut microbiome includes a huge number of bacteria, archaea, fungi, and enteroviruses that colonize the gut. At present, most of the...
-
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per protocol, and enrolment of subjects into Strata B (750g-1000g) will continue. IBT is awaiting advice from the DMC before...
-
Second Genome Announces Milestone Accomplished in Collaboration with Bayer, Demonstrating Broad Application of Company`s Machine Learning Platform to Identify Novel Proteins for the Development of Next-Generation Insect-Control Solutions
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced it has achieved a milestone in its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. “We are pleased to demonstrate successful execution of our collaboration with Bayer and the versatile application of our sg-4sight discovery...
-
Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an oral poster presentation entitled, Predicted Metabolites from Multiple Microbiome Sequencing Datasets Modulate Autism...
-
Lilly`s Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in patients who have completed the 12-week LUCENT-1 induction study is ongoing. UC is a chronic inflammatory disease of the...
Customer comments
No comments were found for Atmo Biosciences’ ingestible gas-sensing capsule to be used in Swedish IBS trial led by Professor Magnus Simrén. Be the first to comment!